

**K223405 Access Testosterone**Jan 13, 2023  
65 days to decisionK223405 · Product code: **CDZ** · Chemistry  
Source: <https://www.510kdatabase.net/k223405/>**SUBMISSION DETAILS**

---

Decision	Substantially Equivalent (Cleared)
Submission type	Traditional
Device classification	Radioimmunoassay, Testosterones And Dihydrotestosterone (CDZ)
Date received	Nov 9, 2022
Decision date	Jan 13, 2023
Days to decision	65 days
Third-party review	No
Combination product	No
PCCP authorized	No
Summary / Statement	Summary

**APPLICANT**

---

Company	<b>Beckman Coulter, Inc.</b>
Location	Chaska, MN, US
Contact	Kuljeet Kaur
Website	<a href="https://www.beckmancoulter.com">https://www.beckmancoulter.com</a>
510(k) history	270 submissions · 270 cleared · 1993-2026

Beckman Coulter, Inc. is a diagnostic device manufacturer headquartered in Chaska, US. The company specializes in clinical laboratory and immunodiagnostic systems. Beckman Coulter has received FDA 510(k) clearances from total submissions since its first clearance in 1993. The company maintains active regulatory status, with the latest clearance in 2026. Its portfolio spans chemistry devices, microbiology testing systems, hematology analyzers, and immunoassay platforms. Recent cleared devices include chemistry assays for cardiac markers, microbiology susceptibility panels,...

---

510k Database - [www.510kdatabase.net](http://www.510kdatabase.net)

Device record: <https://www.510kdatabase.net/k223405/> Data sourced from FDA 510(k) public records ([accessdata.fda.gov](https://accessdata.fda.gov)).

510k Database is an independent platform not affiliated with the U.S. Food and Drug Administration. Always verify at [accessdata.fda.gov](https://accessdata.fda.gov). - Generated May 13, 2026